drugset / Trial / NCT07241338

Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

NCT07241338

Phase 4 Not yet recruiting 104 enrolled Jing Liu
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension

Timeline

Start
2025-11
Primary completion
2026-11
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg Oral
Comparator Amlodipine Other / unclassified 10 mg Oral
Subject Sacubitril Small molecule 240 mg Oral
Subject Sacubitril Small molecule 480 mg Oral